Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has partnered with an unnamed Philippine enterprise to promote its 13-valent and 23-valent pneumonia vaccines in the Philippines. The collaboration aims to enhance regulatory filing, promotion, distribution, marketing, and sales, increasing accessibility and affordability in the Philippines and other emerging markets.
Vaccine Profile
Kangtai Bio’s 13-valent pneumococcal polysaccharide conjugate vaccine, developed via dual carrier technology, avoids adverse effects like immunosuppression linked to single-carrier vaccines. Phase III trials showed non-inferiority to imported products in antibody positive rate and geometric mean titer against 13 pneumococcus serotypes. The vaccine also demonstrated lower adverse reaction rates than the control group.
Strategic Outlook
The partnership reflects Kangtai Bio’s push to expand its vaccine portfolio in emerging markets. By leveraging dual carrier technology, the company aims to provide safer, more effective pneumococcal vaccines globally.-Fineline Info & Tech
